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The mTOR and Hippo pathways have recently
emerged as the major signaling transduction
cascades regulating organ size and cellular homeo-
stasis. However, direct crosstalk between two path-
ways is yet to be determined. Here, we demonstrate
that mTORC2 is a direct negative regulator of
the MST1 kinase, a key component of the Hippo
pathway. mTORC2 phosphorylates MST1 at serine
438 in the SARAH domain, thereby reducing its ho-
modimerization and activity. We found that Rictor/
mTORC2 preserves cardiac structure and function
by restraining the activity of MST1 kinase. Cardiac-
specific mTORC2 disruption through Rictor deletion
leads to a marked activation of MST1 that, in turn,
promotes cardiac dysfunction and dilation, impairing
cardiac growth and adaptation in response to pres-
sure overload. In conclusion, our study demon-
strates the existence of a direct crosstalk between
mTORC2 and MST1 that is critical for cardiac cell
survival and growth.
INTRODUCTION
Cellular growth, proliferation, and survival are critical processes
that must be finely regulated in order to preserve the structure
and function of different organs. The mechanistic (previously
called mammalian) target of rapamycin (mTOR) and Hippo path-
ways have recently emerged as the major signaling transduction
cascades regulating organ size and cellular survival. The mTOR
pathway promotes protein synthesis, cellular growth, and sur-
vival (Laplante and Sabatini, 2012; Wullschleger et al., 2006).
On the other hand, the Hippo pathway exerts opposite effects,
inhibiting cellular growth and proliferation and inducing cell
death (Pan, 2010; Yu and Guan, 2013). This implies that tightcoordination of these two pathways is important for the regula-
tion of organ size and cellular integrity, and it strongly suggests
the existence of multiple crosstalk mechanisms between the
mTOR and Hippo signaling cascades. However, mechanisms
of regulation involving direct crosstalk between the Hippo and
mTOR pathways remain unknown.
mTOR forms two functional multiprotein complexes, known
as complex 1 (mTORC1) and complex 2 (mTORC2), by inter-
acting with specific adaptor proteins. Raptor and Rictor are
the main components of mTORC1 and mTORC2, respectively,
and their deletion causes selective disruption of their respec-
tive complexes (Laplante and Sabatini, 2012; Wullschleger
et al., 2006). Most of what is known about the cellular func-
tions and substrates of mTOR in mammals pertains to
mTORC1. On the other hand, there is still little known about
the biology of mTORC2. Homozygous systemic deletion of
Rictor is embryonically lethal (Guertin et al., 2006; Shiota
et al., 2006; Yang et al., 2006), and inducible systemic Rictor
disruption reduces lifespan (Lamming et al., 2014), suggesting
that mTORC2 is involved in the regulation of important cellular
mechanisms and functions in mammals. However, the cellular
functions, substrates, and molecular mechanisms regulated by
mTORC2 in different tissues and organs still remain to be
clarified.
The Hippo pathway is composed of a group of evolutionarily
conserved protein kinases that inhibit cellular growth and pro-
mote apoptosis (Pan, 2010; Yu and Guan, 2013). The core
component of this group of kinases is MST1, which phosphory-
lates and activates LATS kinases, which in turn phosphorylate
and inhibit YAP1, a co-transcription factor that promotes prolif-
eration and survival. The Hippo pathway is inhibited in several
different types of cancer cells, whereas it is activated during
cellular stress, when it promotes cell-cycle arrest and death
(Pan, 2010; Yu andGuan, 2013). Themechanisms through which
the Hippo pathway is regulated under both unstressed and
stressed conditions are poorly understood.
Tight control over cellular growth and survival appears to be
particularly important in the heart, where regulation of cardiacCell Reports 11, 125–136, April 7, 2015 ª2015 The Authors 125
Figure 1. Rictor/mTORC2 Disruption Pro-
motes Progressive Cardiac Dysfunction
and Dilation
(A) Representative immunoblot showing Rictor
protein levels in control (CT) and Rictor-knockout
mice (R-cKO).
(B and C) Six-month-old CT and R-cKO mice
(heterozygous and homozygous) underwent
echocardiographic analysis. Left ventricular end-
diastolic diameter (LVEDD) and fractional short-
ening (FS) were measured. n = 3–8.
(D and E) Cardiac Masson’s trichrome staining
was performed in left ventricular sections from
CT and R-cKO mice. Representative pictures (D)
and fibrosis quantification (E) are shown. n = 4.
Scale bar represents 50 mm.
(F) The percentage of TUNEL-positive cells was
evaluated in the left ventricle of CT and R-cKO
mice. n = 3.
All data are expressed as mean ± SEM. *p < 0.05;
**p < 0.01.mass and cardiomyocyte survival is critical for homeostasis and
adaptation to stress. The mTOR and Hippo pathways appear to
be important regulators of cellular growth and survival in the
heart as well. Previous studies demonstrated that mTORC1 pro-
motes cardiac growth and preserves cardiac function in the adult
heart through the inhibition of 4E-BP1 protein (Sciarretta et al.,
2014; Shende et al., 2011; Tamai et al., 2013; Zhang et al.,
2010; Zhu et al., 2013). In contrast, activation of MST1 promotes
dilated cardiomyopathy, contributes to cardiomyocyte death
during ischemic injury, and inhibits cardiac growth (Del Re
et al., 2014; Maejima et al., 2013; Yamamoto et al., 2003).
What is still unclear is the importance of mTORC2 in the regula-
tion of cellular growth and survival in the heart, as well as how
MST1 activity is controlled in the heart.
In the present study, we show that mTORC2 is a negative
regulator of MST1 activity in the heart. We found that mTORC2
preserves cardiac structure and function and compensatory
growth in response to mechanical stress by restraining the
activity of MST1. Three main aspects of this study establish its
relevance. The role of mTORC2 in the regulation of cardiomyo-
cyte survival and size in the heart was elucidated. In addition,
MST1 was identified as a substrate of mTORC2 in the regulation126 Cell Reports 11, 125–136, April 7, 2015 ª2015 The Authorsof cellular survival and growth. Finally, we
discovered a mechanism of regulation of
the Hippo pathway and a mechanism of
direct crosstalk between the mTOR and
Hippo pathways.
RESULTS
mTORC2 Is Required for the
Maintenance of Cardiac
Dimensions and Function as well as
Left Ventricular Growth in
Response to Pressure Overload
We dissected the role of mTORC2 in the
heart using a Cre/loxP strategy to condi-tionally delete the Rictor gene in cardiomyocytes (Shiota et al.,
2006). Floxmice carrying aRictor allele in which exon 3 is flanked
by two loxP sites were cross-bred with mice with cardiomyo-
cyte-specific overexpression of Cre recombinase under the con-
trol of the a-myosin heavy chain (MHC) promoter. Mice with
a-MHC-Cre-mediated homozygous deletion of Rictor (R-cKO
mice) displayed a significant reduction in the Rictor protein level
in the heart with respect to control mice (Figure 1A). On the other
hand, the Raptor protein level was unchanged in R-cKO mice
(Figure 1A). R-cKO mice were born alive and developed nor-
mally. At 2 months of age, they did not display any difference
in cardiac dimensions or function with respect to control mice
(Figure S1). However, at 6 months of age, R-cKO mice exhibited
significant cardiac dilation and a reduction of systolic function
with respect to both control mice and mice with heterozygous
Rictor knockout (Figures 1B and 1C). R-cKO mice also showed
a significant increase in cardiac fibrosis and apoptosis, as
indicated by an increased percentage of TUNEL-positive cells
(Figures 1D–1F). These results indicate that mTORC2 is required
for the maintenance of cardiac structure and function in the
adult heart. Of note, the fact that mice with heterozygous
Rictor knockout (Rictor flox/+ and a-MHC-Cre+) did not show
Figure 2. Rictor/mTORC2 Disruption
Impairs Cardiac Adaptation to Pressure
Overload
(A and B) H&E staining was performed in longitu-
dinal heart sections and transverse left ventricular
sections from CT and R-cKO mice. Representa-
tive pictures are shown. Scale bar represents
2 mm.
(C and D) CT and R-cKO mice underwent echo-
cardiographic analysis. Left ventricular end-dia-
stolic diameter (LVEDD) and fractional shortening
(FS) were measured. n = 7–8.
(E and F) Gravimetric analysis was conducted
in CT and R-cKOmice. Lung (E) and left ventricular
(F) weight normalized by tibial length were
calculated. n = 7–8. All data are expressed as
mean ± SEM. *p < 0.05.significant cardiac abnormalities excludes the possibility that
Cre overexpression alone was responsible for the cardiac
phenotype of R-cKO mice.
Next, we subjected young R-cKO mice, which did not show
baseline cardiac abnormalities, as described above, to trans-
verse aortic constriction (TAC), an intervention that imposes
high blood pressure (pressure overload) on the left ventricle of
the heart. After 4 weeks of pressure overload, both longitudinal
and transverse sections of the hearts of R-cKOmice showed sig-
nificant cardiac dilation and wall thinning (Figures 2A and 2B).
Echocardiographic analyses also indicated that R-cKO mice
show cardiac dilation, wall thinning, and systolic dysfunction
as compared to controls after TAC (Figures 2C, 2D, and
S2A–S2C). R-cKO mice also showed more severe signs of
heart failure after TAC, including a marked increase in lung
weight and left ventricular end-diastolic pressure (Figures 2E
and S2D). TAC induced significant left ventricular hypertrophyCell Reports 11, 125–136, April 7, 2015 ª2015 The Authors 127,
t
t
fin both R-cKO and control mice, as indi-
cated by increases in left ventricular
weight/tibia length. However, the TAC-
induced left ventricular hypertrophy was
attenuated in R-cKO mice as compared
to controls (Figure 2F), suggesting a
defect in the hypertrophic response to
TAC in R-cKO mice. This result was also
confirmed by assessment of the cardio-
myocyte cross-sectional area, as evalu-
ated using wheat germ agglutinin staining
of left ventricular tissue sections, which
showed that the increase in cell size
after TAC is modestly but significantly
attenuated in R-cKO mice with respect
to controls (Figures 3A and 3B). Cardiac
apoptosis was also significantly in-
creased in the hearts of R-cKOmice after
TAC, whereas fibrosis was similar in
control mice (Figures 3C–3F). Pressure
overload induced increases in the per-
centage of Ki-67-positive cardiomyo-
cytes in control mouse hearts. HoweverR-cKO mice displayed a lower percentage of Ki-67-positive
cardiomyocytes, suggesting that cardiomyocyte proliferation
in response to pressure overload is attenuated in R-cKO mice
(Figures 3G and 3H). Overall, these results demonstrate tha
R-cKOmice develop severe heart failure in response to pressure
overload. Although heart failure with cardiac dilation and
dysfunction is commonly accompanied by left ventricular hyper-
trophy in order to reduce wall stress, such a compensatory
hypertrophy was attenuated in R-cKO mice. This suggests tha
endogenous Rictor/mTORC2 plays a significant role in medi-
ating cardiac hypertrophy in response to pressure overload.
Rictor/mTORC2 Disruption Promotes Cardiac
Dysfunction and Heart Failure through Deregulated
Activation of MST1
We then investigated the molecular mechanisms through
which Rictor/mTORC2 regulates survival and growth o
Figure 3. Rictor/mTORC2 Disruption Im-
pairs Left Ventricular Growth and Promotes
Apoptosis in Response to Pressure Over-
load
Wheat germ agglutinin, TUNEL, Masson’s tri-
chrome and Ki67 stainings were performed in left
ventricular sections from CT and R-cKO mice at
baseline and after 4 weeks of pressure overload.
(B, D, F, and H) Representative pictures are
shown.
(A, C, E, andG) Cell size (A), percentage of TUNEL-
positive cells (C), percentage of fibrosis (E), and
percentage of Ki67-positive cells (G) were
measured. n = 3–5. n.s., not significant.
All data are expressed as mean ± SEM and as fold
versus CT when specified. *p < 0.05. Scale bar
represents 100 mm.cardiomyocytes. To this end, we evaluated the potential down-
stream signaling pathways of mTORC2 in R-cKO and control
mice at baseline and after 2 days of TAC, which represents an
early phase of pressure overload. This early time point allows
for evaluation of the signaling pathways initially modulated in
response to TAC before heart failure develops and other path-
ways are secondarily altered. AKT phosphorylation at serine
473 was significantly increased after TAC with respect to base-
line in control mice (Figures S3A and S3C), suggesting that
mTORC2 is significantly and rapidly activated in response to
pressure overload. As expected, we found that there was sig-
nificantly less myocardial AKT phosphorylation at serine 473 in
R-cKO mice at baseline and after TAC, whereas phosphory-128 Cell Reports 11, 125–136, April 7, 2015 ª2015 The Authorslation at threonine 308 was unchanged
in R-cKO mice (Figures S3A, S3C, and
S3D). mTORC1 activity, as evaluated by
p70S6 kinase phosphorylation, was
also increased after TAC but did not
differ between R-cKO and control mice
(Figures S3A and S3E). Phosphorylation
of GSK-3b at serine 9 and FOXO1 at thre-
onine 24, two main downstream targets
of AKT, also did not differ between R-
cKO mice and control mice during the
early phase of TAC, although the protein
level of GSK-3b was increased and
FOXO1 phosphorylation was reduced in
the hearts of R-cKO mice after 4 weeks
of TAC (Figures S3A, S3B, and S3F–S3I).
The myocardial activity of MST1, as
evaluated by its autophosphorylation
at threonine 183, was significantly
increased in R-cKO mice as compared
to control mice, both at baseline and after
2 days of TAC (Figures 4A, S4A, and
S4B). MST1 phosphorylation remained
higher in R-cKO mice even after 4 weeks
of TAC (Figures 4B and S4C). In addition,
MST1 cleavage, a marker of strongMST1
and caspase activation, was markedlyincreased in the hearts of R-cKO mice after TAC (Figures 4B
and S4D). Phosphorylation of LATS2 and YAP, two major down-
stream components of the Hippo pathway, was also significantly
increased in R-cKO mice with respect to control mice, both at
baseline and in response to TAC (Figure S4E). MST1 is a main
component of the Hippo pathway, which negatively regulates
organ size through stimulation of apoptosis and inhibition of
cell proliferation (Del Re et al., 2014; Maejima et al., 2013; Pan,
2010; Yamamoto et al., 2003; Yu andGuan, 2013).We previously
demonstrated that cardiac-specific overexpression of MST1 in
transgenic mice (Tg-MST1) promotes cardiac dilation and
dysfunction associated with cardiac fibrosis, apoptosis, and
inhibition of compensatory cardiomyocyte growth (Yamamoto
Figure 4. Rictor/mTORC2 Disruption Pro-
motes Cardiac Dysfunction and Dilation
through MST1 Activation
(A and B) Phosphorylated, total and cleaved levels
of MST1 were evaluated in the hearts of CT and
R-cKO mice at baseline and after pressure over-
load. Representative immunoblots are shown, and
densitometric analyses are shown in Figure S4.
(C) Six-month-old CT, R-cKO, DN-MST1, and
R-cKO+DN-MST1 mice underwent echocardio-
graphic analysis. Fractional shortening (FS) was
measured. n = 3–7.
(D–F) CT, R-cKO, DN-MST1, and R-cKO+DN-
MST1 mice around 10 weeks of age were sub-
jected to 4 weeks of TAC and then underwent
echocardiographic analysis. Left ventricular end-
diastolic diameter (LVEDD), fractional shortening
(FS), and lung weight/tibia length (TL) were
measured. n = 3–7.
All data are expressed as mean ± SEM. *p < 0.05.et al., 2003). The cardiac phenotype of Tg-MST1was remarkably
similar to that observed in R-cKO mice after TAC. We therefore
hypothesized that R-cKO mice develop cardiac dysfunction
and dilation through deregulated activation of MST1 kinase.
In order to test this hypothesis, we cross-bred R-cKO mice
with mice overexpressing dominant-negative MST1 (kinase-
dead MST1) in a cardiomyocyte-specific manner (Yamamoto
et al., 2003). MST1 inhibition by dominant-negativeMST1 almost
completely rescued the cardiac dysfunction observed in
6-month-old R-cKO mice at baseline (Figure 4C). In addition,
we found that MST1 inhibition significantly rescued cardiac
dysfunction and heart failure in young R-cKOmice after 4 weeks
of TAC (Figures 4D–4F). This result indicates that Rictor/
mTORC2 disruption promotes cardiomyopathy and heart failure
through MST1 activation.
Rictor/mTORC2 Phosphorylates MST1 in the SARAH
Domain, Thereby Reducing Its Dimerization and Activity
mTORC2 may regulate MST1 activity either directly or indirectly
through the modulation of AKT activity. In fact, AKT was previ-Cell Reports 11, 125ously found to inhibit MST1 (Collak et al.,
2012). Rictor knockdown in cardiomyo-
cytes in vitro was associated with a
marked activation of MST1 that could
not be rescued by concomitant over-
expression of constitutively active AKT
(Figure S5). This result suggests that
mTORC2 may regulate MST1 in cardio-
myocytes independently of AKT. In addi-
tion, previous studies demonstrated that
AKT1 knockout mice do not show any
baseline cardiac abnormalities, whereas
they develop a marked increase in car-
diac hypertrophy with respect to control
mice after TAC (DeBosch et al., 2006),
which is different from the phenotype of
R-cKO mice that show attenuated left
ventricular hypertrophy after TAC. There-fore, we tested the hypothesis that mTORC2 can directly regu-
late MST1 activity. Rictor and MST1 were partially co-localized
in cardiomyocytes, mainly in the perinuclear region, which is
consistent with the previously reported localization of Rictor
and MST1 in the ER (Boulbe´s et al., 2011; Maejima et al., 2013)
(Figure 5A). In addition, we found that endogenous Rictor inter-
acts with MST1 in themouse heart in vivo and in cardiomyocytes
in vitro (Figures 5B and S6A).
Next, we evaluated whether mTORC2 can phosphorylate
MST1. Since mTORC2 is a multiprotein complex composed of
several proteins that are required for its activity, in order to test
whether mTORC2 can phosphorylate specific substrates, we
needed to purify mTORC2 from a biological system by immuno-
precipitating Rictor, incubating it with a specific substrate, and
performing in vitro kinase assays (Sarbassov et al., 2005). We
used kinase-dead MST1 as a substrate to avoid the strong
MST1 autophosphorylation that is usually observed when
wild-type MST1 is used in kinase assays (Maejima et al., 2013).
Phosphorylation of MST1 by mTORC2 was unaffected by an
AKT inhibitor but was abrogated by Torin1, an mTOR-specific–136, April 7, 2015 ª2015 The Authors 129
Figure 5. Rictor/mTORC2 Phosphorylates MST1 at Serine 438
(A) Immunocytofluorescence assay of Rictor and MST1 was performed in neonatal rat cardiomyocytes transduced with either control adenovirus or an
adenovirus expressing a short-hairpin sequence targeting Rictor or MST1. Representative pictures are shown. A higher magnification of a portion of the merged
panel of control sample is shown in the inset. Scale bar represents 50 mm.
(B) Rictor was immunoprecipitated frommouse left ventricle. Immunoprecipitate with control IgG was used as control. Representative immunoblots of Rictor and
MST1 are shown.
(legend continued on next page)
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inhibitor (Thoreen et al., 2009) (Figure 5C). These results suggest
that mTORC2 phosphorylates MST1 through an mTOR-depen-
dent but AKT-independent mechanism. In order to identify the
MST1 phosphorylation site, mass spectrometry analysis was
conducted on recombinant MST1 phosphorylated by mTORC2.
The result of the mass spectrometry analysis indicated that
mTORC2 phosphorylates MST1 at serine 438 (Figure 5D). This
residue of MST1 is evolutionarily conserved across different
species, although serine may be substituted with threonine in
non-mammalian species (Figure 5E). Serine 438 is located in
the SARAH domain of MST1 (Figure 5F), which is highly
conserved from lower organisms to mammals and is of crucial
importance for MST1 dimerization, autophosphorylation and
subsequent activation (Praskova et al., 2004).
Using an antibody that is specific against MST1 phosphory-
lated at serine 438 (Figures S6B–S6D), we confirmed that
mTORC2 phosphorylates MST1 at serine 438, after mTORC2
kinase reaction using recombinant MST1 as a substrate (Fig-
ure 5G). We also found that phosphorylation of MST1 at this
site is significantly reduced in the hearts of R-cKO mice (Fig-
ures 5H and S4F) and in cardiomyocytes with Rictor depletion
in vitro (Figure S5). On the other hand, phosphorylation of
MST1 at serine 438 was significantly increased in response to
TAC, suggesting that MST1 phosphorylation by mTORC2 is
increased during cardiac stress (Figures 5H and S4F). Interest-
ingly, we found that insulin, a known activator of mTORC2
(Lamming et al., 2012; Xie et al., 2011) and cellular growth,
induces MST1 phosphorylation at serine 438 in cardiac fibro-
blasts. In contrast, mTOR inhibition by Torin1 significantly
inhibited serine 438 phosphorylation and induced a marked
increase in MST1 autophosphorylation (Figure S6E). These re-
sults suggest that mTORC2 also regulates and phosphorylates
MST1 in other cell types as well as in cardiomyocytes and
that serine 438 phosphorylation negatively regulates MST1
activation.
Given that MST1 was dramatically activated and autophos-
phorylated in R-cKO mice, we hypothesized that MST1 phos-
phorylation at serine 438 by endogenous mTORC2may interfere
with the dimerization and activation ofMST1. To test this hypoth-
esis, wild-type, serine 438 phosphorylation-resistant mutant and
serine 438 phosphorylation-mimicking mutant MST1, with either
MYC or FLAG tags, were expressed in cells in different combina-
tions, and co-immunoprecipitation assays were conducted. The
dimeric interaction between phosphomimetic MST1 mutant
(S438D) and wild-type MST1 was significantly less than that
between two wild-type MST1 proteins or between phosphore-
sistant MST1 mutant (S438A) and wild-type MST1 (Figure 6A).
These results indicate that phosphorylation of MST1 at serine
438 interferes with MST1 dimerization.(C) Kinase reaction was performed with the specified proteins. 50 mM of 1L-6-hyd
of Torin1 was used when specified. A representative autoradiograph is shown. A
analysis to test the levels of FLAG-DN-MST1, Rictor, and mTOR.
(D) Analysis of the MST1 peptide by tandem mass spectrometry after incubation
(E) Conservation of MST1 serine 438 across different species is shown.
(F) Schema representing the localization of the serine 438 residue in the MST1 S
(G) A kinase reaction was performed with recombinant MST1 in the presence or ab
MST1 phosphorylation at serine 438 was evaluated.
(H) Cardiac phosphorylation levels of MST1 at serine 438 were evaluated in CT aOverexpression of either wild-type or S438AMST1was able to
significantly increase the phosphorylation of the downstream
target LATS2 in cardiomyocytes. In contrast, S438DMST1 failed
to induce significant phosphorylation of LATS2 (Figures 6B and
6C). Finally, overexpression of either wild-type or S438A MST1
significantly reduced cardiomyocyte survival. On the other
hand, overexpression of S438D MST1 in cardiomyocytes failed
to induce significant cell death (Figure 6D). Overall, these results
indicate that mTORC2-dependent phosphorylation of MST1
at serine 438 inhibits MST1 homodimerization and activity, as
well as MST1-induced cell death.
DISCUSSION
The mTOR kinase is a master regulator of cellular growth and
survival (Laplante and Sabatini, 2012; Wullschleger et al.,
2006). However, the cellular processes and downstream
signaling pathways specifically regulated by mTORC2 still
remain to be clarified. Here, we demonstrate the existence of a
direct connection between mTORC2 and the Hippo pathway.
Disruption of mTORC2 leads to deregulated activation of
MST1 that causes cardiomyocyte apoptosis and cardiac
dysfunction while, at the same time, suppressing compensatory
myocardial growth. Thus, our study provides evidence indicating
that mTORC2 promotes cellular growth and survival by restrain-
ing MST1 activity. In addition, we clarified a direct signaling
link between the mTOR and Hippo pathways that is crucial for
the preservation of cardiac function and growth in response to
stress.
mTORC2 phosphorylates MST1 at serine 438 in the SARAH
domain and reduces its ability to homodimerize and become
activated. The SARAH domain is a highly conserved module
located in the C-terminal portion of MST1 that is necessary for
homodimerization (Praskova et al., 2004). The SARAH domain
is also involved in heterodimerization with other SARAH-
domain-containing scaffolds, including RASSF1A, NORE1, and
SAV1, that regulate MST1 activity as well (Pan, 2010; Praskova
et al., 2004; Yu and Guan, 2013). A previous crystallographic
analysis of the MST1 SARAH domain homodimer indicated
that serine 438 is located between helix h1 and helix h2 and,
together with tryptophan 439, it forms a bifurcated hydrogen
bond with phenylalanine 435 (Hwang et al., 2007). This bifur-
cated hydrogen bond formation plays an important role in stabi-
lizing the kinked conformation of helix h1 against helix h2, which
in turn facilitates the autophosphorylation of the kinase domain
of MST1. We speculate that phosphorylation of serine 438 may
disturb the kinked conformation of the helix h1/h2, thereby inter-
fering with both MST1 homodimerization and autophosphoryla-
tion. In addition, the crystallographic structure of the homodimerroxymethyl-chiro-inositol2-[(R)-2-O-methyl-3-O-octadecylcarbonate] or 1 mM
portion of the samples used in each kinase reaction was used for immunoblot
with the mTORC2 complex in a kinase reaction.
ARAH domain.
sence of mTORC2. Torin1 was used when specified. After the kinase reaction,
nd R-cKO at baseline and after TAC. Immunoblots are shown.
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Figure 6. MST1 Phosphorylation at Serine
438 Reduces Its Dimerization and Activity
(A) COS7 cells were transfected with the specified
plasmids. MYC was immunoprecipitated, and
immunoblots for MYC and FLAG are shown.
Immunoprecipitate with control IgGwas used as a
control.
(B and C) Cardiomyocytes were transduced with
ad-LacZ, ad-FLAG-WT-MST1, ad-FLAG-S438A-
MST1, or ad-FLAG-S438D-MST1. After 48 hr,
the levels of phospho-LATS2 (T1041 homolo-
gous), total LATS2, and MST1 were evaluated,
and representative immunoblots are shown (B)
together with quantification analysis of the
P-LATS2/LATS2 ratio (C). n = 3.
(D) After 72 hr, cardiomyocyte survival was
assessed by CellTiter-Blue assay. n = 4. All data
are expressed as mean ± SEM. *p < 0.05; n.s., not
significant.
(E) Schema representing the negative regulation
of MST1 by mTORC2, which preserves cell
survival.ofMST1 SARAH domains (Hwang et al., 2007) also suggests that
serine 438 on one molecule of MST1 is located close to the
aspartate 475 and glutamate 478 residues located on the other
molecule of MST1. Thus, phosphorylation of serine 438 would
interfere with the dimerization of MST1 through electrostatic
repulsion (Figure S6F). Finally, as already mentioned, it is also
possible that phosphorylation of serine 438 would modulate
the ability of MST1 to hetero-dimerize with RASSF/SAV1
proteins.
Previous studies indicated that, at physiological levels, Hippo
signaling controls cellular growth and maintains organ structure,
whereas deregulated Hippo signaling activation during stress
is maladaptive and causes apoptosis and cell death (Pan,
2010; Yu and Guan, 2013). We believe that an important function
of mTORC2 is to be a ‘‘guardian’’ of MST1 activity, finely control-
ling when MST1 activation is physiological or detrimental. In this132 Cell Reports 11, 125–136, April 7, 2015 ª2015 The Authorsregard, we observed that MST1 activity
is increased in the hearts of wild-type
mice during pressure overload. MST1 is
activated under this condition through
several upstream molecules, such as
RASSF1a and KRAS, which were previ-
ously found to mediate MST1 activation
during cardiac stress (Del Re et al.,
2010, 2014). However, we found that
mTORC2-dependent phosphorylation of
MST1 is also increased during pressure
overload and that when mTORC2 is dis-
rupted, MST1 activity further increases
and cardiac dysfunction occurs. This
suggests that the activity of mTORC2
toward MST1 is increased under this
condition in order to maintain MST1 acti-
vation within physiological limits and pre-
serve cardiac function. Other molecules
also appear to have similar functions,acting to keep the level of activity of MST1 low. For example,
NORE1 was shown to restrain MST1 activity in vivo (Praskova
et al., 2004). In addition, previous work indicated that RAF1 pro-
tein inhibits apoptosis and promotes cell survival by preventing
the dimerization and activation of MST2 (O’Neill et al., 2004).
Our study significantly extends this evidence and demonstrates
that phosphorylation of MST1 by mTORC2 is another mecha-
nism for limiting MST1 activity. Of note, this inhibitory mecha-
nism appears to be specific for MST1, since the other MST iso-
form, MST2, lacks the serine 438 site in its primary structure. In
addition, recent evidence indicates that MST2 exerts pro-hyper-
trophic effects in cardiomyocytes and does not regulate cardiac
function in response to pressure overload (Zi et al., 2014). This
diverges from the known anti-hypertrophic and pro-heart-failure
effects of MST1 in the heart and from the cardiac effects of
mTORC2 disruption, as we demonstrated in our study. This prior
evidence coupled with our results suggest that the detrimental
effects of mTORC2 disruption are mediated by MST1 activation,
whereas MST2 is likely not involved but warrants further study.
mTORC2 positively regulates cellular growth and survival,
mainly through the positive regulation of AKT (Jacinto et al.,
2006; Jacinto et al., 2004; Sarbassov et al., 2005). The
mTORC2/AKT pathway was also found to be associated with
cardiomyocyte protection during ischemic injury (Vo¨lkers et al.,
2013; Yano et al., 2014). We believe that our study significantly
expands upon this evidence by demonstrating that mTORC2
is also able to regulate cellular growth and survival in specific
cell types and conditions through the direct inhibition of MST1.
Of note, previous evidence from Guan’s laboratory indicated
that YAP, a main target of inhibition by the Hippo pathway, can
activate AKT through miR-29-mediated inhibition of PTEN
(Tumaneng et al., 2012). These data, combined with our
results, indicate that mTORC2 can regulate AKT activity both
directly and indirectly through the inhibition of the Hippo
pathway and the resulting activation of YAP. In addition, AKT
and MST1 were previously shown to mutually inhibit each other
(Cinar et al., 2011; Collak et al., 2012). Thus, the mTORC2
and Hippo pathways can engage in crosstalk at multiple
levels. Of note, mTORC2 was also shown to activate SGK1
and PRKCA/PKC-a (Facchinetti et al., 2008; Garcı´a-Martı´nez
and Alessi, 2008; Ikenoue et al., 2008). However, it is very
unlikely that these factors are involved in the detrimental effects
of mTORC2 deletion in the heart, since inhibition of either
SGK1 or PKC-a protects the heart against hemodynamic stress
(Braz et al., 2004; Das et al., 2012).
We believe that the molecular mechanisms presented in our
study have broad biological implications. mTORC2 was previ-
ously shown to positively regulate survival of cancer cells (Lap-
lante and Sabatini, 2012). On the other hand, the components
of the Hippo pathway are onco-suppressors that are inhibited
in different types of cancer (Pan, 2010). Our study suggests
thatmTORC2may regulate carcinogenesis through the inhibition
of Hippo signaling. In this regard, recent work reporting the re-
sults of a large-scale proteomics analysis of the human kinome
conducted in leukemia, colon, and breast cancer cell lines
showed that MST1 is phosphorylated at serine 438 in all of these
cancer cell lines, whereas MST1 autophosphorylation could not
be detected, indicating MST1 inhibition (Oppermann et al.,
2009). These results are consistent with our evidence indicating
that phospho-serine 438 inhibits MST1 activity. Notably,
mTORC2 was shown to mediate survival of leukemia, colon,
and breast cancer cell lines (Laplante and Sabatini, 2012; Wulls-
chleger et al., 2006).
Another potential and relevant implication of the connection
between mTORC2 and the Hippo pathway relates to the control
of cytoskeleton organization. mTORC2 was previously shown to
promote actin polymerization and F-actin accumulation, through
which it regulates cell migration and proliferation (Jacinto et al.,
2004). On the other hand, the components of the Hippo pathway
exhibit opposite effects on cytoskeleton organization, inhibiting
actin polymerization and F-actin accumulation (Ferna´ndez
et al., 2011). Our results suggest that mTORC2 may also pro-
mote actin formation indirectly through inhibition of the Hippo
pathway. F-actin accumulation induced by mTORC2 may alsorepresent an indirect mechanism of regulation of the Hippo
pathway bymTORC2, since actin polymerization results in Hippo
signaling inhibition and YAP1 activation (Aragona et al., 2013;
Zhao et al., 2012).
Our data may also be relevant to completely different biolog-
ical systems and organisms. For example, amphibians are
among the organisms with the highest regenerative capacity.
The frog Xenopus laevis was shown to be able to regenerate
amputated limbs through the activation of YAP, suggesting
Hippo pathway inhibition (Hayashi et al., 2014). Of note, in the
MST1 homolog in X. laevis, serine 438 is substituted with
aspartic acid, suggesting a lower MST1 activity, which is con-
sistent with an increased regenerative ability.
In conclusion, our study demonstrates the existence of
crosstalk between the mTORC2 and Hippo pathways. We
believe that the mTORC2/MST1 signaling cascade is a critical
regulator of cell survival and growth in cardiomyocytes and,
potentially, in other biological systems (Figure 6E).
EXPERIMENTAL PROCEDURES
Animal Models
The generation of Rictor flox mice was previously described (Shiota et al.,
2006). Rictor exon 3 was targeted in these animals. Flox mice were cross-
bred with a-MHC-Cre transgenic mice in order to generate R-cKO mice.
a-MHC-DN-MST1 (K59R) transgenic mice (C57BL/6J background) were
previously described (Yamamoto et al., 2003). R-cKO mice were cross-
bred with Tg-DN-MST1 mice. All mice were studied on a C57BL/6J back-
ground. Control (CT), R-cKO, and R-cKO+DN-MST1 mice were subjected
to TAC to induce pressure overload, as previously described (Yamamoto
et al., 2003). Briefly, mice were anesthetized with pentobarbital sodium.
The left chest was opened and mice were ventilated. Aortic constriction
was performed by ligation of the transverse thoracic aorta with a 26G needle
using a 7-0 braided polyester suture. Echocardiographic and hemodynamic
analyses were performed as previously described (Maejima et al., 2013;
Yamamoto et al., 2003). All protocols concerning animal use were approved
by the institutional animal care and use committee at Rutgers New Jersey
Medical School.
Cell Cultures, Plasmid Constructs, Transfection,
and Adenovirus Generation
Primary cultures of ventricular cardiomyocytes were prepared from 1-day-
old Crl:(WI) BR Wistar rats (Charles River Laboratories) as described previ-
ously (Maejima et al., 2013). Percoll gradient centrifugation was performed
to separate the cardiomyocyte fraction from other cellular fractions. Cells
were cultured in DMEM/F-12 medium. HEK293 cells and COS7 cells were
maintained as previously described (Maejima et al., 2013). Neonatal rat
cardiac fibroblasts were isolated, passaged, and maintained as previously
described (Del Re et al., 2010). MYC-Rictor expression construct was from
Addgene (Sarbassov et al., 2004). WT-MST1, AKT1, S438A-MST1, and
S438D-MST1 cDNAs were subcloned into pDC316 vector (Maejima et al.,
2013; Morisco et al., 2001; Yamamoto et al., 2003). Lipofectamine 2000
(Invitrogen) was used for transfection. Adenovirus vector generation was
conducted as described previously (Yamamoto et al., 2003). The DE1 adeno-
viral genome incorporated in pBHGloxDE1,3Cre (Microbix) was co-trans-
fected with the pDC316 shuttle vector harboring the cDNA of interest into
HEK293 cells.
Immunoprecipitation and Immunoblot Analysis
Left ventricular tissue homogenates or cell cultures were lysed with CHAPS
buffer (40 mM HEPES [pH 7.5], 120 mM NaCl, 1 mM EDTA, 0.3% CHAPS)
for mTORC2 immunoprecipitation or with IGEPAL CA-630 buffer (50 mM
Tris-HCl [pH 7.4], 1% IGEPAL CA-630, 10 mM EDTA, 150 mM NaCl), together
with a protease inhibitor cocktail (Sigma-Aldrich). For FLAG-DN-MST1Cell Reports 11, 125–136, April 7, 2015 ª2015 The Authors 133
immunoprecipitation, cells were lysed with a buffer containing 50 mM Tris-HCl
(pH 7.5), 300 mMNaCl, 1% Triton X-100, 0.5% deoxycholic acid, 1 mM EDTA,
and protease inhibitors.
Lysates were incubated with the specified antibody and the immunocom-
plexes were precipitated using A/G Sepharose beads for at least 2 hr at 4C.
After immunoprecipitation, the samples were washed five times and were
used for in vitro kinase assay reactions or for immunoblotting after immunopre-
cipitate elution.
Immunoblot analysis was performed as previously described (Maejima
et al., 2013). For this analysis, tissue or cellular samples were lysed in RIPA
buffer with 0.1 mM Na3VO4, 1 mM NaF, 1 mM b-glycerophosphate, and
protease inhibitor cocktail from Sigma-Aldrich.
In Vitro Kinase Assay
MYC-Rictor was immunoprecipitated from HEK293 cells to isolate mTORC2
as described previously (Dibble et al., 2009; Sarbassov et al., 2004; Treins
et al., 2010). mTORC2 was incubated with purified FLAG-DN-MST1 in the
presence of mTORC2 kinase buffer (25 mM HEPES [pH 7.4], 100 mM potas-
sium acetate, and 1 mM MgCl2), together with 500 mM of ATP, with or without
10 mCi [g-32P] ATP per reaction for 20 min at 37C, as previously described
(Dibble et al., 2009; Ikenoue et al., 2009; Sarbassov et al., 2006; Sarbassov
et al., 2005). The AKT inhibitor 1L-6-hydroxymethyl-chiro-inositol2-[(R)-2-O-
methyl-3-O-octadecylcarbonate] (Biovision, Cat# 1701-1) or Torin1 (Tocris,
Cat# 4247) was used when specified. Phosphorylated proteins were sepa-
rated by SDS-PAGE and analyzed by autoradiography.
Mass Spectrometry
After kinase reaction with recombinant MST1 protein (1 mg), the samples
were separated by SDS-PAGE and the MST1 band was excised for in-gel
trypsin digestion. The resulting peptides were subjected to liquid chromatog-
raphy-tandem mass spectrometry analysis on the Orbitrap Velos tandem
mass spectrometry instrument (Thermo Scientific) using a nanoelectrospray
source with a spray voltage of 2 kV. Mass spectrometry (MS) spectra were
acquired in a positive ion mode. MS/MS spectra were acquired using colli-
sion-induced dissociation (CID) in a data-dependent manner. The lock
mass was used for accurate mass measurements. The MS/MS spectra
were searched against Swiss-Prot human database using the Mascot
search engine. The following search parameters were used: trypsin was
selected as the enzyme with 1 missed cleavage; peptide precursor mass
tolerance of 10 ppm; and MS/MS mass tolerance of 0.5 Da. Methionine
oxidation, serine and threonine phosphorylation, and cysteine carbamidome-
thylation were selected as variable modifications. The phosphopeptides
and their phosphorylation sites were verified with PhosphoRS software
(Thermo Scientific).
Immunofluorescence and Staining
Cellular and tissue immunofluorescence were conducted according to a
previously described method (Maejima et al., 2013). Briefly, neonatal rat
cardiomyocytes plated on chamber slides (Lab-Tek) were fixed with 4% para-
formaldehyde and permeabilized with PBS containing 0.1% Triton X-100.
Mouse left ventricles were fixed in formalin and sectioned at 10-mm thickness.
Tissue sections were then subjected to deparaffinization and antigen unmask-
ing using citrate buffer and washed with PBS containing 0.3% Triton X-100.
Samples were then blocked for 1 hr with PBS containing 5% BSA in vitro
experiments or with normal goat serum in vivo, and then incubated with
primary antibody overnight. Cells were then incubated with Alexa 488- and
Alexa Fluor 568-conjugated secondary antibodies (Invitrogen) for 3 hr. Nuclei
were stained with DAPI. Images were taken using either conventional or
confocal microscopy. For TUNEL staining, we used the In Situ Cell Death
Detection kit (Roche) according to the manufacturer’s instructions. Masson’s
trichrome, H&E, and wheat germ agglutinin staining were conducted as
previously described (Del Re et al., 2013; Maejima et al., 2013).
Cell Survival Assay
Cardiomyocyte survival was assessed using the CellTiter-Blue assay from
Promega, according to the manufacturer’s instructions.134 Cell Reports 11, 125–136, April 7, 2015 ª2015 The AuthorsAntibodies
Polyclonal antibody against MST1 phosphorylated at serine 438 was raised
in rabbits and generated by 21st Century Biochemicals. The immunizing
peptides were GDYEFLK[pS]WTVEDL and DYEFLK[pS]WTVEDLQ. Phos-
pho-LATS2 (Thr1041) was kindly provided by Dr. Nojima (Osaka University).
Other commercially available antibodies used in the study include Rictor,
MST1 (P-Thr183), MST1 (N terminus), Raptor, AKT1 (P-Ser473), AKT1
(P-Thr308), AKT1, p70S6K (P-Thr389), GSK-3b (P-Ser9), GSK-3b, FOXO1
(P-Thr32/24), FOXO1, YAP1 (Ser127), YAP1, GAPDH, anti-mouse, anti-
rabbit, conformation-specific anti-rabbit, and FLAG from Cell Signaling;
MST1 (C terminus) from BD Transduction; p70S6K and Rictor from Santa
Cruz Biotechnology; FLAG, FLAG-agarose beads, MYC, and Tubulin from
Sigma-Aldrich; Rictor and LATS2 from Bethyl Laboratories; Ki-67 from
Vector Laboratories; Troponin T from Neomarkers; and Alexa 488 donkey
anti-goat immunoglobulin G (IgG), Alexa 488 goat anti-rabbit IgG, Alexa Fluor
594 goat anti-mouse IgG, and Alexa Fluor 568 donkey anti-mouse IgG from
Invitrogen.
Statistics
Data are expressed as mean ± SEM. The t test was used when the difference
in means between two groups was evaluated. One-way ANOVA followed by
the Bonferroni post hoc test was used when the comparison analysis was
extended to multiple groups. Statistical analyses were performed with the
use of GraphPad-Prism 5.00 (GraphPad-Software). p values of < 0.05 were
considered statistically significant.
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